Larimar Therapeutics Inc Stock News

BALA CYNWYD, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company's management team will present and participate in 1x1 investor meetings at the 44th Annual J.P.

In the open label (OL) study, after 6-months of daily nomlabofusp administration, 100% of participants (n = 10) achieved skin FXN levels similar to asymptomatic carriers Consistent directional improvement across mFARS, FARS-ADL, 9-HPT and MFIS after 1-year in OL study reinforces the potential of nomlabofusp to alter FA's disease course relative to a worsening in a FACOMS natural history study r...

LOS ANGELES , Oct. 16, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of Larimar Therapeutics, Inc. ("Larimar" or "the Company") (NASDAQ: LRMR) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to inves...

LOS ANGELES--(BUSINESS WIRE)--Larimar Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – LRMR.

Larimar Therapeutics, Inc. - Special Call Company Participants Carole Ben-Maimon - CEO, President & Director Conference Call Participants Alexandra Folias Yatin Suneja - Guggenheim Securities, LLC, Research Division Joori Park - Leerink Partners LLC, Research Division Samantha Semenkow - Citigroup Inc., Research Division Joon Lee - Truist Securities, Inc., Research Division Myles Minter - Willi...

BALA CYNWYD, Pa., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced positive 25 mg and 50 mg data from the ongoing long-term open label (OL) study evaluating daily subcutaneous injections of nomlabofusp self-administered or administered by a ca...

Conference call and webcast on Monday, September 29, 2025 at 8:00 am EDT Conference call and webcast on Monday, September 29, 2025 at 8:00 am EDT

* Pro forma cash, cash equivalents, and marketable securities of $203.6 million reflects $138.5 million of cash, cash equivalents and marketable securities as of June 30, 2025 combined with the $65.1 million in net proceeds from the recently completed July 2025 public offering.